Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults
Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)
DOI: 10.1002/cpdd.70085 ↗At a glance
Klinische Studie (Phase I) in Clinical Pharmacology in Drug Development, published online on 2026-07-24. Written by Fumio Otsuka and 7 co-authors. Institution: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Major MEDLINE topics: Receptors, Somatostatin. 27 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Paltusotine is a novel, nonpeptide, once‐daily oral, selective somatostatin 2 receptor (SST2) agonist. We evaluated the pharmacokinetics, pharmacodynamics, and safety of oral paltusotine in healthy Japanese adults in single‑dose (20, 40, 60, 80 mg) and repeated‑dose (40 mg once daily for 7 days in a two‐sequence, two‑period crossover design) studies. In addition, the effects of food intake and pharmacodynamics were examined in the repeated‐dose study. Eight participants were enrolled in each dose of the single‐dose study, and 12 participants were enrolled in the repeated‐dose study. In both studies, there were no deaths, serious adverse events, or severe adverse events. In the single‐dose study, plasma paltusotine exposures increased in a dose‐dependent manner for the dose range of 20 to 80 mg (based on C max and AUC 0‐∞ ), and the elimination half‐life (t 1/2 ) was 24‐28 h. In the repeated‐dose study, similar reductions from baseline in serum insulin‐like growth factor‐1 (IGF‐I) were observed for 1‐h pre‐prandial (−60.1 ± 26.0 ng/mL) and 3‐h post‐prandial administration (−61.6 ± 17.7 ng/mL) on Day 7. Overall, this study establishes the pharmacokinetics, pharmacodynamics, and safety in healthy Japanese adults to support the development of paltusotine as a treatment for acromegaly and pituitary gigantism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Medical Affairs Group, Medical Affairs Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
- Project Management Group, Project Management Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
- Clinical Development Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
- Crinetics Pharmaceuticals, Inc., San Diego, USA.
- Souseikai Sumida Hospital, Tokyo, Japan.
Cite
APA
Otsuka, F., Hanabara, K., Akari, S., Kitamoto, K., Inagaki, Y., Glatt, D., Murakami, H., & Uchida, N. (2026). Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70085
Vancouver
Otsuka F, Hanabara K, Akari S, Kitamoto K, Inagaki Y, Glatt D, et al. Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70085
BibTeX
@article{Otsuka2026,
author = {Otsuka, Fumio and Hanabara, Keiko and Akari, Seigo and Kitamoto, Katsunori and Inagaki, Yosuke and Glatt, Dylan and Murakami, Harumi and Uchida, Naoki},
title = {Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cpdd.70085}
}
EUVIMED